$RGR (Sturm, Ruger & Co. Inc.)

$RGR {{ '2016-08-03T18:08:57+0000' | timeago}} • Announcement

$RGR said its President and COO Christopher Killoy will succeed Michael Fifer as CEO upon Fifer's planned retirement at the next Annual Meeting on May 9, 2017. The BoD also voted to lift number of Directors to 9 and elected Killoy as Director, effective immediately. Fifer will continue to support $RGR as Vice Chairman after retirement.

$A {{ '2018-01-09T19:50:20+0000' | timeago}} • Announcement

$A acquired Cork, Ireland-based Luxcel Biosciences, a developer of real-time fluorescence plate-reader based in vitro cell assay kits. This acquisition expands $A's cell analysis portfolio with the addition of easy-to-use assay kits that are compatible with industry standard plate-readers.  Financial terms of the deal were not disclosed.

$AOBC {{ '2017-12-07T23:34:23+0000' | timeago}} • Announcement

$AOBC now sees 3Q18 net sales of $170-180MM generating a GAAP EPS of $0.01-0.04 and adjusted EPS of $0.07-0.10. For FY18, the firearm maker expects net sales of $650-675MM generating a GAAP EPS of $0.33-0.43 and adjusted EPS of $0.57-0.67.

$AOBC {{ '2017-12-07T23:31:45+0000' | timeago}} • Announcement

With wholesaler and retailer orders slumping, iconic Smith & Wesson firearm maker $AOBC saw quarterly net sales slump 36% to $148.4MM in 2Q18. Net income reduced to a measly $3.2MM or $0.06 per diluted share, about one-tenth f om last year's $32.5MM or $0.57 per diluted share.

$A {{ '2017-11-21T15:04:12+0000' | timeago}} • Webcast

For FY18, $A expects pharma to moderate down slightly from a 6% growth rate delivered in FY17. Agilent expects China to maintain a high-single-digit growth rate. For Europe and the chemical and energy markets, while Agilent experienced unexpectedly strong FY17 growth, the company cautiously guided to lower growth in FY18.

$A {{ '2017-11-20T21:43:30+0000' | timeago}} • Announcement

$A expects 1Q18 revenue of $1.145-1.165Bil. First-quarter non-GAAP earnings are expected to be in the range of $0.55 to $0.57 per share. For FY18, Agilent expects revenue of $4.72-4.74Bil and non-GAAP earnings of $2.50-2.56 per share.

$A {{ '2017-11-20T21:40:09+0000' | timeago}} • Announcement

With net revenue soaring 7% to $1.19Bil in 4Q17, $A posted a 40% jump in net income of $177MM or $0.54 per diluted share.

$AA {{ '2017-10-13T16:51:21+0000' | timeago}} • Announcement

$AA and Luminant Generation Company LLC have terminated the electricity contract associated to $AA's Rockdale Operations in Texas. The termination of the contract, which had been set to expire around 2038, was effective October 1, 2017.

$VSTO {{ '2017-10-05T21:14:37+0000' | timeago}} • Announcement

$VSTO's BoD said Christopher Metz will serve as its CEO, effective Oct. 9, 2017. He will also serve as a board member. During 2Q18 BoD meeting, the board will appoint a permanent Chairman and until that date, Michael Callahan will continue to serve as Interim Chairman, and Ambassador April Foley will continue to serve as Lead Independent Director.

$RGR {{ '2017-10-04T13:52:21+0000' | timeago}} • Announcement

$RGR repurchased a total of 243,423 common shares at aggregate cost of $11.3MM. These repurchases, which accounted for 1.4% of the outstanding shares as of July 1, 2017, were funded with cash on hand. At end of 3Q, $88.7MM remained authorized and available for share repurchases and 17.4MM shares of common stock remained outstanding.

$A {{ '2017-09-22T21:43:23+0000' | timeago}} • Announcement

$A said its Dako PD-L1 IHC 22C3 pharmDx assay has an expanded label approved by the US FDA to aid in identifying gastric or GEJ adenocarcinoma patients for treatment with KEYTRUDA, an anti-PD-1 therapy manufactured by $MRK. These approvals mean these patients have the possibility of receiving a targeted anti-PD-L1 immunotherapy.

$A {{ '2017-09-20T20:44:35+0000' | timeago}} • Announcement

$A has declared a quarterly dividend of 13.2 cents per share on its common stock. The dividend will be paid on October 25, 2017, to shareholders of record on October 3, 2017.

$A {{ '2017-09-19T15:03:27+0000' | timeago}} • Announcement

$A said FDA has approved the cancer diagnostic known as PD-L1 IHC 28-8 pharmDx for use in cases of urothelial carcinoma and of squamous cell carcinoma of the head and neck. The test had previously been approved for melanoma as well as non-squamous, non-small-cell lung cancer (NSCLC).

$A {{ '2017-09-13T19:05:54+0000' | timeago}} • Announcement

$A has obtained approval from the US FDA for the GenetiSure Dx Postnatal Assay, its first comparative genomic hybridization (CGH) assay for diagnostic use. This assay enables clinical geneticists to detect genetic aberrations associated with developmental delay, intellectual disabilities and congenital irregularities more accurately.

$VSTO {{ '2017-09-13T14:40:24+0000' | timeago}} • Announcement

$VSTO announced the appointment of Hermann Hartje as the new distributor of CamelBak Products, LLC in Austria starting October 1, 2017. Thalinger Lange GmbH will serve the brand’s retail partners through September 30, 2017. Hermann Hartje is based in Hoya an der Weser, Germany.

$AOBC {{ '2017-09-11T19:28:36+0000' | timeago}} • Webcast

According to $AOBC, both Gemtech and Bubba Blade transactions closed after the end of 1Q18 for an aggregate purchase price of $22MM. AOBC expects about $7MM of revenue from these businesses in FY18.

$AOBC {{ '2017-09-11T19:19:43+0000' | timeago}} • Webcast

$AOBC, as it posted 1Q18 results, said that its Firearm units shipped into the consumer channel in the quarter declined by 39.1%, with handgun unit shipped into the consumer channel slumping 34.6% and long gun unit shipped sliding 57.1%.

$AOBC {{ '2017-09-11T18:29:11+0000' | timeago}} • Infographic

$AOBC American Outdoor Brands Corporation Earnings AlphaGraphic: Q1 2018 Highlights

$AOBC {{ '2017-09-11T13:52:40+0000' | timeago}} • Announcement

While posting a fall in 1Q18 sales, $AOBC also updated its FY18 earnings outlook to be in the range of $1.04 to $1.24 per share, while the revenue forecast calls for sales between $700MM and $740MM.

$AOBC {{ '2017-09-11T13:51:18+0000' | timeago}} • Announcement

With an underwhelming revenue of $129.0MM slumping 38% in 1Q18, $AOBC posted a loss of $2.2MM or $0.04 per diluted share vs. last year's net income of $35.2MM or $0.62 per diluted share.

$A {{ '2017-08-23T13:21:45+0000' | timeago}} • Announcement

Life sciences company $A filed a lawsuit against its former employees and Shanghai Echrom Electronic Technology, alleging infringement of trade secrets. The suit seeks compensation for the loss and stoppage of the use of Agilent's proprietary technologies by Shanghai Echrom and others. The employees allegedly obtained the trade secrets illegally.

Recent Transcripts

AOBC (American Outdoor Brands Corporation)
Thursday, December 7 2017 - 10:00pm
A (Agilent Technologies Inc.)
Monday, November 20 2017 - 9:30pm
AIRI (Air Industries Group)
Thursday, November 16 2017 - 1:30pm
VSTO (Vista Outdoor Inc.)
Thursday, November 9 2017 - 2:00pm
RGR (Sturm, Ruger & Co. Inc.)
Wednesday, November 1 2017 - 1:00pm
ACU (Acme United Corp.)
Friday, October 20 2017 - 3:00pm
AA (Alcoa Inc.)
Wednesday, October 18 2017 - 9:00pm
AOBC (American Outdoor Brands Corporation)
Thursday, September 7 2017 - 9:00pm
AIRI (Air Industries Group)
Wednesday, August 16 2017 - 8:00pm
A (Agilent Technologies Inc.)
Tuesday, August 15 2017 - 8:30pm
VSTO (Vista Outdoor Inc.)
Thursday, August 10 2017 - 1:00pm
RGR (Sturm, Ruger & Co. Inc.)
Thursday, August 3 2017 - 1:00pm
ACU (Acme United Corp.)
Tuesday, July 25 2017 - 4:00pm
AA (Alcoa Inc.)
Wednesday, July 19 2017 - 9:00pm
AOBC (American Outdoor Brands Corporation)
Thursday, June 29 2017 - 9:00pm
A (Agilent Technologies Inc.)
Monday, May 22 2017 - 8:30pm
VSTO (Vista Outdoor Inc.)
Thursday, May 11 2017 - 1:00pm
RGR (Sturm, Ruger & Co. Inc.)
Tuesday, May 9 2017 - 12:00am
AA (Alcoa Inc.)
Monday, April 24 2017 - 9:00pm
ACU (Acme United Corp.)
Thursday, April 20 2017 - 4:00pm

AlphaGraphics you may like